Updated: Roche, Ionis launch new Huntington’s disease study
SAN FRANCISCO — A new study for the Huntington’s disease drug tominersen, developed in tandem by Roche and Ionis, “is open and has started screening eligible patients,” a Roche spokesperson told Endpoints News on Wednesday. The Phase II trial will examine whether tominersen can slow the progression of Huntington’s in patients aged 25 to 50 with very early or subtle signs of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.